RTW Biotech OpportunitiesLSE:RTW +1.24%36 PB Ratio is 0.92 as of Jul. 02, 2026, which is 19% above its 10-year median of 0.77. GuruFocus rates LSE:RTW with a GF Score™ of 36/100. The stock has 2 warning signs investors should review. Among 1,599 Asset Management companies, RTW Biotech Opportunities ranks better than 57.41% on this metric.
The historical rank and industry rank for RTW Biotech Opportunities's PB Ratio or its related term are showing as below:
LSE:RTW'
s PB Ratio Range Over the Past 10 Years
Min: 0.54 Med: 0.77 Max: 1.45
Current: 0.93
During the past 8 years, RTW Biotech Opportunities's highest PB Ratio was 1.45. The lowest was 0.54. And the median was 0.77.
LSE:RTW's PB Ratio is ranked better than 57.41% of 1599
companies
in the Asset Management industry
Industry Median: 0.96
vs LSE:RTW: 0.93
During the past 12 months, RTW Biotech Opportunities's average Book Value Per Share Growth Rate was 40.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 17.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 3.90% per year.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of RTW Biotech Opportunities was 64.90% per year. The lowest was -1.80% per year. And the median was 7.30% per year.
Back to Basics: PB Ratio
RTW Biotech Opportunities (LSE:RTW) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
RTW Biotech Opportunities PB Ratio Related Terms
RTW Biotech Opportunities PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Asset Management subindustry, RTW Biotech Opportunities's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RTW Biotech Opportunities PB Ratio vs Asset Management Industry
For the Asset Management industry and Financial Services sector, RTW Biotech Opportunities's PB Ratio distribution charts can be found below:
* The bar in red indicates where RTW Biotech Opportunities's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
RTW Biotech Opportunities (LSE:RTW) has a PB Ratio of 0.92 as of Jul. 02, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on RTW Biotech Opportunities and its competitors. This is 19% above median its historical median of 0.77. Over the past decade, RTW Biotech Opportunities' PB Ratio has ranged from 0.54 to 1.45. According to the industry distribution chart, RTW Biotech Opportunities ranks #681 out of 1599 companies in the Asset Management industry, placing it in the top 42.6%.
Is RTW Biotech Opportunities' PB Ratio too high?
RTW Biotech Opportunities' current PB Ratio of 0.92 is 19% above median its 10-year median of 0.77. Over the past 10 years, this metric has ranged from a low of 0.54 to a high of 1.45. The Asset Management industry median PB Ratio is 0.96. RTW Biotech Opportunities' value of 0.92 is 4.2% below this industry median. Based on the distribution chart, RTW Biotech Opportunities ranks #681 out of 1599 companies in the Asset Management industry, which is above the industry midpoint. Overall, RTW Biotech Opportunities has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does RTW Biotech Opportunities' PB Ratio compare to BLK and BX?
According to the Asset Management industry distribution chart, RTW Biotech Opportunities ranks #681 out of 1599 companies for PB Ratio. This puts RTW Biotech Opportunities in the upper half of its industry. The industry median PB Ratio is 0.96. RTW Biotech Opportunities' value of 0.92 is 4.2% below this benchmark. Historically, RTW Biotech Opportunities' own PB Ratio has ranged from 0.54 to 1.45 over the past decade. While the company's 10-year median is 0.77 vs. the industry median of 0.96, RTW Biotech Opportunities has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for an Asset Management company?
The median PB Ratio among Asset Management companies is 0.96, based on 1,599 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RTW Biotech Opportunities's current PB Ratio of 0.92 is 4.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on RTW Biotech Opportunities and its competitors. For the Asset Management industry, the median PB Ratio is 0.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RTW Biotech Opportunities's current PB Ratio is 0.92, which is 19% above median its own 10-year median of 0.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RTW Biotech Opportunities stock overvalued right now?
RTW Biotech Opportunities (LSE:RTW) has a current PB Ratio of 0.92. The current PB Ratio is 0.92, which is 19% above median its 10-year median of 0.77 and 4.2% below the Asset Management industry median of 0.96. RTW Biotech Opportunities' overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For RTW Biotech Opportunities (LSE:RTW), the current PB Ratio is 0.92 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
RTW Biotech Opportunities Ltd is a life sciences and investment fund focused on identifying transformative assets with high growth potential across the biopharma and medtech sectors. It is powering medical breakthroughs that have the potential to transform the wellbeing of people around the world. Its portfolio includes Neurology, Oncology, Inflammation, Cardiovascular, Metabolic, Pulmonary, Ophthalmology, Rare Disease, and Other. Geographically it operates in USA & Canada, the Rest of World, and UK & EU, with the majority of the revenue deriving from USA & Canada.
36GF Score
Get the complete analysis for LSE:RTW
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:RTW has been successfully added to your 
